Insider filing · OLMA

G. Walmsley Graham bought $4.7M of Olema Pharmaceuticals (OLMA)

Executed Dec 13 2024, disclosed Dec 18 2024, 5 days later, against a two-business-day limit.

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

GG G. Walmsley Graham Director profile →

G. Walmsley Graham (Director) filed 5 Form 4 reports in the past 24 months (3 purchases, 3 sales, 3 filed past the two-business-day deadline; 1 filing reported both), most often in Olema Pharmaceuticals, Inc. (OLMA). The largest single filing was $9.6M of AKRO (200,000 sh × $48.00, as filed), executed Jan 30 2025. The median gap between execution and disclosure was 5 days.

OLMA Olema Pharmaceuticals, Inc. OLMA · Healthcare · 17 filings in 24 months ticker →

Healthcare · Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of th…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→